Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

G1 Therapeutics Inc (GTHX)

G1 Therapeutics Inc (GTHX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 373,809
  • Shares Outstanding, K 52,281
  • Annual Sales, $ 82,510 K
  • Annual Income, $ -47,970 K
  • 60-Month Beta 1.66
  • Price/Sales 4.58
  • Price/Cash Flow N/A
  • Price/Book 15.20
Trade GTHX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.86
  • Most Recent Earnings $-0.10 on 08/08/24
  • Next Earnings Date 11/06/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.12
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.17
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +65.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.08 +0.99%
on 08/19/24
7.19 -0.56%
on 08/27/24
+0.04 (+0.56%)
since 08/16/24
3-Month
1.44 +395.84%
on 06/24/24
7.19 -0.56%
on 08/27/24
+4.48 (+167.79%)
since 06/17/24
52-Week
1.08 +562.04%
on 10/09/23
7.19 -0.56%
on 08/27/24
+5.61 (+364.29%)
since 09/15/23

Most Recent Stories

More News
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

ONCY : 1.2300 (+6.96%)
ACLX : 88.15 (+1.54%)
ONC.TO : 1.70 (-0.58%)
GTHX : 7.15 (unch)
HALO : 54.20 (+0.46%)
SNY : 54.71 (-0.38%)
Biotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Cases

USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common...

ONCY : 1.2300 (+6.96%)
ONC.TO : 1.70 (-0.58%)
GILD : 86.11 (+1.25%)
GTHX : 7.15 (unch)
AZN : 77.52 (-0.74%)
HOLX : 82.26 (+0.78%)
Biotech Innovations Paving the Way in Breast Cancer Fight

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END

ONCY : 1.2300 (+6.96%)
ONC.TO : 1.70 (-0.58%)
GILD : 86.11 (+1.25%)
GTHX : 7.15 (unch)
AZN : 77.52 (-0.74%)
HOLX : 82.26 (+0.78%)
First Prescription for COSELA® (trilaciclib) Issued in China

/PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) ("Simcere"), an innovative global biopharmaceutical company, and G1 Therapeutics, Inc., (Nasdaq:...

GTHX : 7.15 (unch)
Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

/PRNewswire/ -- USA News Group - A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of...

ONC.TO : 1.70 (-0.58%)
ONCY : 1.2300 (+6.96%)
LLY : 909.86 (-2.11%)
NEO : 13.95 (+1.01%)
ZYME : 13.61 (+2.33%)
GTHX : 7.15 (unch)
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)

EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END

ONCY : 1.2300 (+6.96%)
ONC.TO : 1.70 (-0.58%)
LLY : 909.86 (-2.11%)
NEO : 13.95 (+1.01%)
ZYME : 13.61 (+2.33%)
GTHX : 7.15 (unch)
Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

USA News Group – A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year’s...

ONCY : 1.2300 (+6.96%)
ONC.TO : 1.70 (-0.58%)
LLY : 909.86 (-2.11%)
NEO : 13.95 (+1.01%)
ZYME : 13.61 (+2.33%)
GTHX : 7.15 (unch)
G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript

GTHX earnings call for the period ending June 30, 2022.

GTHX : 7.15 (unch)
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights

- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue - - Completed...

GTHX : 7.15 (unch)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...

GTHX : 7.15 (unch)

Business Summary

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc....

See More

Key Turning Points

3rd Resistance Point 7.18
2nd Resistance Point 7.17
1st Resistance Point 7.16
Last Price 7.15
1st Support Level 7.14
2nd Support Level 7.13
3rd Support Level 7.12

See More

52-Week High 7.19
Last Price 7.15
Fibonacci 61.8% 4.86
Fibonacci 50% 4.14
Fibonacci 38.2% 3.41
52-Week Low 1.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar